1. Scrip
  2. >>Business
  3. >>Deals

Astellas Builds Vaccine Portfolio With Affinivax Pneumococcal Candidate

 
• By Ian Haydock

Despite one recent setback, Astellas is continuing to expand its vaccines business through a new global deal for Affinivax's lead MAPS pneumococcal product, in a move that builds on earlier research links between the companies.

Antibiotic resistant bacteria closeup biofilm

Astellas Pharma Inc. is paying $10m upfront to acquire exclusive worldwide rights to develop and commercialize a novel pneumococcal disease vaccine developed by Affinivax Inc. using the US venture's proprietary Multiple Antigen Presenting System (MAPS) technology.

The candidate, used to prevent infections caused by the Streptococcus pneumoniae bacterium including pneumonia, meningitis, and sepsis, is Affinivax's lead pipeline project and is still at

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.